How Pharmacokinetic Modeling Works: The Real Math Behind an Absorption Curve

When you take a peptide or GLP-1 injection, nothing about your body's response is instant, and nothing about it is flat. A compound enters your system, rises to a peak, and decays back out — and the shape of that rise and fall is not a guess. It's governed by well-established pharmacokinetic math that's been used in drug development for decades. This article walks through that math in plain terms: what it actually calculates, and why a "plasma level" number on a tracking app means something more specific than "you took a dose today."

The core model: one compartment, first-order kinetics

The simplest, most widely used way to describe how a compound behaves in the body after a single dose is the one-compartment model with first-order absorption and elimination. "One compartment" means the body is treated, for modeling purposes, as a single well-mixed pool the compound enters and leaves — a simplification, but a useful and standard one. "First-order" means both the absorption (getting into that pool) and the elimination (getting cleared out of it) happen at rates proportional to how much compound is currently present, not at a fixed amount per hour.

That behavior is captured by the Bateman function:

C(t) = Dose · F · ka / (ka − ke) · (e^(−ke·t) − e^(−ka·t))

Breaking that down:

• C(t) is the estimated relative concentration at time t after the dose.
• Dose is the amount administered.
• F is bioavailability — the fraction of the dose that actually reaches general circulation. An intravenous dose has F = 1 (100%) by definition; other routes lose some fraction to absorption inefficiency.
• ka is the absorption rate constant — how quickly the compound moves from the injection/administration site into circulation.
• ke is the elimination rate constant — how quickly the body clears it.

The two exponential terms are doing the actual shape-drawing: e^(−ka·t) describes the absorption phase dying out as the compound finishes entering circulation, and e^(−ke·t) describes the ongoing elimination. Early on, absorption dominates and the curve rises. Once absorption is essentially complete, elimination takes over and the curve decays. The peak — the moment those two effects balance — sits at a specific, calculable point in time, not wherever a chart happens to be drawn.

Where half-life comes from

You'll often see a compound described by its "half-life" rather than its raw elimination rate. The two are directly related:

ke = ln(2) / half-life

This is just algebra on the definition of a half-life: it's the amount of time for concentration to fall by 50%, and solving the decay equation C(t) = C(0) · e^(−ke·t) for that condition gives you ke = ln(2)/half-life directly. A compound with a 2-hour half-life clears roughly twice as fast (in rate terms) as one with a 4-hour half-life — though because the relationship is exponential, not linear, "twice the rate" doesn't mean "twice the time to fully clear."

What happens with an IV dose, or when absorption and elimination rates are nearly identical

Two edge cases are worth knowing about, because a naive implementation of the formula above breaks on both.

For an intravenous dose, there's no meaningful absorption phase at all — the compound is already in circulation the instant it's administered. The model correctly branches to simple mono-exponential decay, C(t) = Dose · e^(−ke·t), rather than trying to force an absorption term that doesn't apply.

For any route where ka happens to be very close to ke, the original Bateman formula has a division by (ka − ke) in it — and as ka approaches ke, that denominator approaches zero, which would produce nonsense (or an outright error) in a naive calculation. The correct handling is to take the mathematical limit as ka → ke, which resolves to a clean closed form: C(t) = Dose · ke · t · e^(−ke·t). This isn't an approximation or a patch — it's the actual limiting behavior of the same underlying model, just expressed differently at that one specific boundary condition.

Multiple doses: superposition, not restarting the clock

Real-world tracking rarely involves a single isolated dose — it involves a protocol, with doses repeating on a schedule. The mathematically correct way to handle this is linear superposition: each individual dose produces its own independent curve, computed exactly as above from its own administration time, and the total plasma level at any given moment is simply the sum of every still-relevant dose's contribution at that moment. Nothing about a new dose erases or restarts the decay of a previous one — it just adds another curve on top of it, which is why doses taken close together (relative to the compound's half-life) show visible accumulation, while doses spaced far apart don't meaningfully overlap at all.

Why this matters for tracking, not just theory

The practical payoff of all this math is that a plasma-level chart isn't decorative — every point on it is derived from the actual timing and amount of what you logged, using the same category of model real pharmacology uses to describe drug behavior. It's why the curve for a subcutaneous dose looks meaningfully different from an intramuscular one at the same amount, why a compound with a long half-life visibly "stacks" across a week of daily dosing while a short-half-life one resets close to zero between doses, and why adjusting an assumption (like your own half-life estimate) reshapes the whole picture consistently rather than arbitrarily.

None of this is a substitute for medical guidance, and it isn't intended as one — it's a transparent description of what the underlying number actually represents, so it means something more concrete than "I took something today."